Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
about
Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasA gist of gastrointestinal stromal tumors: A review.Diagnosis and evaluation of gastric cancer by positron emission tomographyGEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Reintroduction of imatinib in GISTF-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors.Controversies in the management of gastrointestinal stromal tumors.The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases.A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
P2860
Q28483929-B03F2548-D842-4611-B5D4-6F2A2AA0E800Q34654203-971D357D-99A3-45F0-8787-902EE5C9442CQ34661633-6627C4DF-746C-4FE1-8C6D-88AC29437F4EQ34664305-464F437F-BF66-407B-B85A-6EC8850D97AFQ36694926-3014D651-42DC-4F33-9524-4EB30DFD457EQ37301364-8F83A4F5-E4C9-49E2-B81D-C42E7A10A1DDQ37944803-F7F79332-EAE8-442F-AD66-2712D04CAEB9Q38199797-D834DBB3-30D8-4E99-BC5D-F5ECA93BC082Q38661189-08E2A050-6488-4F64-9CC9-B6D2A458D5E7Q38925022-72E33381-E26E-45F3-9CF9-859993C895B0Q52957653-B7B88576-8F26-45AB-B322-39CBA7238C4BQ54497681-EE6AFAEB-E53B-4377-9CD1-DEA66A366CDAQ54645672-81207876-C110-4BC3-8324-182762C2FBB9
P2860
Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
type
label
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
prefLabel
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
P2093
P356
P1433
P1476
Imatinib plus low-dose doxorub ...... Group for Research on Sarcomas
@en
P2093
Ana Sofia Martins
Andrés Poveda
Antonio Casado
Antonio Lopez-Pousa
Javier Martínez-Trufero
Joan Maurel
José Antonio López-Guerrero
Juan Ramón Ayuso
Ricardo Cubedo
Xabier Garcia-Albeniz
P304
P356
10.1002/CNCR.25111
P407
P577
2010-08-01T00:00:00Z